All targets of Amaryllidaceae alkaloids identified to date, i.e., ribosomes, eEF1α, and recently STAT3, must be considered in the design of compounds to combat both CRC cells and the tumor microenvironment. This evidence concerns the gene EEF1A1 and colorectal carcinoma.